BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$70.10 USD
-0.19 (-0.27%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $70.22 +0.12 (0.17%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
Income Statements
Fiscal Year end for BioMarin Pharmaceutical Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,419 | 2,096 | 1,846 | 1,860 | 1,704 |
Cost Of Goods | 515 | 484 | 471 | 524 | 359 |
Gross Profit | 1,904 | 1,612 | 1,376 | 1,336 | 1,345 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,746 | 1,463 | 1,458 | 1,373 | 1,445 |
Income After Depreciation & Amortization | 158 | 150 | -82 | -37 | -100 |
Non-Operating Income | 48 | 16 | 22 | 24 | 29 |
Interest Expense | 17 | 16 | 15 | 29 | 23 |
Pretax Income | 189 | 150 | -75 | -42 | -95 |
Income Taxes | 21 | 8 | -11 | -901 | -71 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 168 | 142 | -64 | 859 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 168 | 142 | -64 | 859 | -24 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 253 | 255 | 31 | 69 | 3 |
Depreciation & Amortization (Cash Flow) | 95 | 105 | 113 | 106 | 103 |
Income After Depreciation & Amortization | 158 | 150 | -82 | -37 | -100 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 191.60 | 188.96 | 182.85 | 191.68 | 179.04 |
Diluted EPS Before Non-Recurring Items | 1.23 | 0.89 | 0.25 | 0.68 | 0.07 |
Diluted Net EPS (GAAP) | 0.87 | 0.75 | -0.35 | 4.53 | -0.13 |
Fiscal Year end for BioMarin Pharmaceutical Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 712.03 | 648.83 | 646.21 | 581.33 | 595.28 |
Cost Of Goods | 130.46 | 125.18 | 135.48 | 124.75 | 128.08 |
Gross Profit | 581.57 | 523.65 | 510.73 | 456.58 | 467.19 |
SG&A, R&D, and Dept/Amort Expenses | 461.12 | 435.20 | 434.29 | 430.92 | 408.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | 120.45 | 88.45 | 76.44 | 25.66 | 58.87 |
Non-Operating Income | 15.26 | 20.63 | 11.21 | 19.79 | 15.70 |
Interest Expense | 3.57 | 3.55 | 6.10 | 3.78 | 3.76 |
Pretax Income | 132.14 | 105.55 | 19.33 | 41.67 | 70.81 |
Income Taxes | 24.96 | 16.89 | -1.05 | 1.29 | 14.77 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 107.17 | 88.66 | 20.38 | 40.38 | 56.04 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 107.17 | 88.66 | 20.38 | 40.38 | 56.04 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 200.51 | 199.26 | 191.84 | 191.17 | 195.00 |
Diluted EPS Before Non-Recurring Items | 0.77 | 0.49 | 0.26 | 0.26 | 0.34 |
Diluted Net EPS (GAAP) | 0.55 | 0.46 | 0.10 | 0.21 | 0.29 |